Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC
Status:
Recruiting
Trial end date:
2025-04-01
Target enrollment:
Participant gender:
Summary
This open-label, multicenter, randomized phase II study will evaluate the usage of
osimertinib alone for brain metastases compared to SRS and osimertinib in patients with newly
diagnosed, treatment naiive EGFR positive lung cancer.
Phase:
Phase 2
Details
Lead Sponsor:
British Columbia Cancer Agency
Collaborators:
AstraZeneca AstraZeneca Canada Princess Margaret Hospital, Canada Sunnybrook Health Sciences Centre